Page 367 - Binder2

The regulatory inertia, the IP framework, the sunk costs of
stainless-steel plants and monoclonal pipelines. But even
the thickest walls crack when pressure mounts—and the
pressure is building. Payers can’t afford the status quo.
Patients are demanding access. The global south is tired of
waiting for medicine that never comes.

This isn’t a fringe idea anymore. It’s pharma’s worst
nightmare—because it dares to ask the one question the
industry hoped no one would:

What if drugs didn’t need to be this expensive, exclusive,
and injected at all?

And once you ask that,
there’s no going back.

365